After over one year clinical studies on several female cancer patients with breast surgery, the method was classified into risk-group III (lowest risk), and a review committee was established which surveys the selection of patients and the process of therapy, according to Japanese regulations.

Nikkei Biotech news release, Jan 26, 2015